On May 16, Axinn partner Chad Landmon will speak on the "FDA (Still) Under Fire: Pending SCOTUS Decisions on Agency Deference" panel at the Food and Drug Law Institute's Annual Conference, being held May 15-16 in Washington, DC.

The U.S. Supreme Court will soon decide two cases centered on judicial deference to FDA on statutory interpretation and science-based decision making (Looper Bright Enterprises v. Raimondo and FDA v. Alliance for Hippocratic Medicine, respectively). Panelists will review the case history and arguments and discuss potential ramifications for the industry and the agency if judicial deference to FDA is limited or eliminated for either.

Click here for more information, including how to register.